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analgesic medication, VAS range was required to be between
40 mm and 90 mm. Lastly, all subjects were required to have a
Body Mass Index < 35.
For this multiple baseline, repeated measures design, all sub-
jects were evaluated for 3 baseline visits at 2 week intervals.
At the third baseline visit, subjects were then given an 8-week
course of celecoxib (200 mg/d). Outcome measures continued
to be collected at 2 week intervals during the 8 week course
of medication. At each of the seven total visits, subjects com-
pleted the VAS version of the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain, stiffness and
function scales; performed three trials of the Timed Up and Go
Test (TUG); and walked 24 feet for five trials across a com-
puterized gait mat that recorded velocity, cadence, step length,
and double support time. Means from all tests were calcu-
lated for each visit. The baseline values were averaged to more
accurately assess function prior to beginning medication. This
baseline value and data from the four bi-weekly medication ses-
sions were entered into one-way repeated measures ANOVAs
to determine within-group differences for each of the dependent
variables (p = 0.05). Paired t-tests were employed for post hoc
analyses.
Results: Results of the ANOVA indicated that subjects signifi-
cantly increased walking velocity (p=.029) and cadence (p=.001),
with post hoc tests indicating significant differences from base-
line at week 8 for velocity and weeks 6 and 8 for cadence. While
modest improvements occurred in step lengths and double limb
support time, the differences were not statistically significant. All
subjects significantly improved on their TUG scores (p=.009) and
on all aspects of the WOMAC (function: p=.005, pain: p=.019,
stiffness: p=.001).
Conclusions: Walking velocities improved steadily during the
eight week course of celecoxib. We believe the faster walking
speeds resulted because subjects took more steps rather than
longer steps. The effect of the medication on reducing symptoms
of pain and stiffness may account for a greater freedom of limb
movement, whereby subjects could more freely advance their
lower limbs, take additional steps, and improve efficiency of their
walking.
In addition to symptomatic relief of pain and stiffness, subjects
improved in all aspects of their walking performance. These
positive findings also support the use of a clinically-based, in-
strumented gait analysis to determine the effectiveness of this
medication on walking function in individuals with knee OA.
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A NEW ANKLE CONDRAL LESIONS CLASSIFICATION -
E. Di Cave, F.V. Sciarretta, P. Versari, A. Basile
Jewish Hospital, Rome, Italy
Purpose: Aim of this study has been the identification of a
treatment algorythm based on the proposal a new ankle chondral
lesion classification, that took in consideration the need to better
localize, understand and commonly relate the different chondral
lesions patterns, diagnosed on MRI and confirmed and treated
by ankle arthroscopy, both in the distal tibia and in the talar
dome. Last ten years dilemma in such lesions treatment has
focused on talus lesions staging, that, in our opinion represents
just the 2/3 of the problem, neglecting the thorough examination
of the distal tibia articular surface lesions.
Methods: Initially we needed to create a classification of carti-
lage ankle lesions in order to identify a common language both
for the diagnosis then the planning and treatment of the le-
sions.One of the main problems to solve was that of evaluating,
beyond the talus lesions, until now considered alone, the distal
tibia extremity lesions wich until now have been in impingement
classification. We therefore searched for the most adequate and
homogeneous classification to answer the needs of foot and an-
kle surgeons in daily practice, searching for common parameters
between MRI -CT- RDX - Arthroscopic findings
Results: The goal of the classification we have developed proved
to be very usefull in the planning of the correct corresponding
surgical treatment.
As reported in the lecterature early detection and treatment
facilitates better outcome.
This is not only confirmed by our study, but we have found that
talus lesion starting from ll degree is very often associated to
a minor tibial plafond lesion, often understimated, secondary to
microinstability or to axial malalignement that in our experience
has required an associated high tibial osteotomy.
Conclusions: The rationale of this classification consists in
giving each lesion a precise identification of position subdiving in
A tibia, B talus as main lesions, 1-2-3 medial third, medial, lateral
third, "a" tibia and "b" talus as secondary lesions (were present)
We felt that it was important to mantain the classification of
Berndt and harty with regards to the depth and the anatomo-
pathological lesions found.
For the staging of the lesions with the new classification the
following will be used:
es. grade A2blll to define a lesion that has main localization
the tibia, the medial position, secondary localization in the talus
dome and grading of the lesion lll.
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Purpose: Whole body vibration (WBV) has been proposed as
an effective exercise intervention because of its potential for
increasing force generating capacity in the lower limbs, and
a training effect on the neuromuscular system. Knee OA is
associated with decreased muscular strength and neuromuscular
function in the lower extremities. The aim of this study was to
evaluate whether WBV would be able to improve muscle function
of the lower extremities and balance and to improve the patients
pain and physical signs of knee OA. In addition two different
WBV devices were compared, one with vibration alone (VibMax)
and one with vibration combined with the demand of keeping the
body equilibrium during WBV (ViBrosFär).
Methods: 52 female patients with knee OA, fulfilling the ACR-
criteria, volunteered to participate in this study. Their mean age
was 60.5 years (SD 9.9) and their mean Body Mass Index
was 28.8 kg/m2 (SD 4.5). Patients with other chronic diseases
or artificial knee or hip joint were excluded from the study.
Before randomization, the proprioception (measured as knee
joint position sense, JPS and threshold to detection of a passive
movement, TDPM), ability to climb up and downstairs on time,
walking on time, standing balance on a force plate and isometric
muscle strength was measured. In addition the patients filled in
the SF-36 and WOMAC questionnaires. Patients randomized to
either ViBrosfär (balance plate with laterally vibration, 24 - 30
Hz, 1-2 mm amplitude, Vibrosfär, ProMedVi, Sweden) or VibMax
(stable plate with both laterally and vertical vibration, 25-30 Hz,
1 1/2-4 mm amplitude, Vibmax, Xendon, Sweden) exercised two
times per week for eight weeks. The exercise progression was
standardized and equal for both exercise groups. A third group
acted as control group.
Results: Baseline values of proprioception showed a total mean
for all three groups of JPS: 5.5° (SD 2.6°) and for TDPM: 2.6°
(SD 1.1°); total mean for all three groups for climbing six steps
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up and down three times: 29.6 s (SD 12.5 s) and walking 50
m: 34.4 s (SD 8.7 s); standing balance showed a total mean
for all three groups of average angular velocity: 1.3 m ·s-1 (SD
0.3 m ·s-1), per cent maximum stability: 65.3 (SD 10.9) and per
cent ankle strategy: 70.4 (SD 10.3); isometric muscle strength
showed a total mean for all three groups of knee extension: 72.3
Nm (SD 25.6 Nm) and knee flexion: 37.5 Nm (SD 12.6 Nm).
Conclusions: Preliminary results indicates that WBV may affect
the muscle function and balance in patients with knee OA. How-
ever, analysis is in progress, and the final results and conclusions
will be presented at the congress.
Pain and Disability
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Purpose: Significant risk factors in development of knee os-
teoarthritis (OA) has shown to be quadriceps weakness, joint
instability, and changes in joint loading. Few studies have looked
at these risk factors for hip OA. Furthermore, very few studies,
have reported biomechanical changes in gait patterns affecting
joint loading. There are no studies so far describing both biome-
chanics during gait (joint loading) and clinical outcomes in hip OA
patients. The purpose of this study was to identify biomechanical
and clinical characteristics among patients with hip OA.
Methods: Fifty patients aged 60.0 (±10.3) years, 32 women
and 18 men, with hip pain >3months, activity limitations, and
radiographically verified hip OA were included consecutively.
Gait analysis was performed using Qualisys Pro reflex 3D mo-
tion analysis system, including three forceplates (AMTI). Fur-
thermore, the disease specific questionnaire,WOMAC, isokinetic
muscle strength (TechnoRev9000), sub-maximal cardiovascular
function (Åstrand’s bike-test), hip range of motion, and 6 minute
walk test, the generic health-related quality of life questionnaire
(SF-36v2), self-efficacy for pain, and the physical activity scale
for the elderly, PASE, were included.
Results: The WOMAC showed a mean total score of 25.9
(±15.4) mm, 26.9 (±17.3) mm for pain, 34.4 (±21.5) mm for
stiffness, and 24.6 (±15.7) mm for physical function subscales.
There was a significant decrease in peak isokinetic muscle
strength for the involved versus the uninvolved side for: hip-
extension 142.2 Nm versus 152.9 Nm (p<0.05), knee-extension
104.7 Nm versus 117.4 Nm (p<0.001), knee-flexion 64.1 Nm
versus 67.4 Nm (p<0.05), and ankle-plantarflexion 63.3 Nm ver-
sus 67.6 Nm (p<0.05). The gait analysis showed biomechanical
changes in the involved versus the non-involved hip and knee.
Conclusions: The WOMAC showed a clinically acceptable state
for pain and physical function among the studied patients,
however, the patients showed significantly decreased muscle
strength for hip extension, knee extension and flexion, and an-
kle plantar flexion. Decreased muscle strength is a significant
risk factor for the development of knee OA and should there-
fore be targeted in these subjects. Both a randomized controlled
trial, regarding the effect of exercise therapy, and a case-control
study, identifying biomechanical and clinical characteristics, are
ongoing.
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Purpose: Research supports that the direct activation of the
Beta-Endorphinergic Systems (BES)could successfully decrease
the level of pain experienced. The "NEXALIN" design uses a
proprietary wave form (US Patent 6,904,322 B2), based on
a quasi resonance frequency of 77.5 Hz. This frequency was
confirmed in many prior Russian trials and studies, as being key
to stimulating the increase in concentration of beta-endorphins
in the brain, spinal fluid and blood (SU Patent #1522500). The
aim is to prove the possibility of decreasing pain caused by
osteoarthritis (OA) by using transcranial electrostimulation (TES)
via the "NEXALIN" device.
Methods: The study was multi-centered, randomized, double-
blind, and placebo-controlled. The study population consisted of
211 patients who had been diagnosed with OA of knee and/or
hip, had a pain history of at least three months, and scored 4 or
more on the Visual Score for Pain Assessment. The "NEXALIN"
groups received 7 daily TES session of 40 minutes, 15 mA (root
mean square); the placebo group received no stimulation using
a visually identical device. Assessment methods: pain level (PL),
patient global self-assessment (PGA), walking test (WT), physi-
cian’s assessment (PA) - all utilizing visual scales. Assessments
were performed prior to treatment, during the treatment series,
and at the 1 year follow-up assessment.
Results: After 7 treatments: PL decreased in the "NEXALIN"
group 57%, placebo 24% (p<10-9), WT 54% and 30% (P<10-
4); PGA and PA increased respectively 47% and 25% (P<0.04),
44% and 32% (P<0.03).
After 2 weeks: PL decreased in the "NEXALIN" group 40%,
placebo 21% (p<10-4), WT 42% and 30% (P<0.01); PGA and
PA increased respectively 29% and 25% (P<0.66), 42% and
30%(P<0.01).
Statically analysis also showed decreasing of PL in the "NEX-
ALIN" group during at least 6 weeks.
The number and type of side effects were equivalent in both
groups, with quantities in placebo exceeding active.
Conclusions: "NEXALIN’s" TES device, realized through activa-
tion of BES, provides significant and prolonged decrease in pain
associated with OA,
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Pennsylvania, Philadelphia, PA
Purpose: Chronic knee/hip pain, most commonly due to os-
teoarthritis (OA), is a leading cause of disability in the elderly.
Joint replacement is a cost-effective treatment option for ad-
vanced knee/hip OA. However, there is marked racial/ethnic
disparity in the utilization of joint replacement. The reasons for
this disparity remain poorly understood and might include dif-
ferential access to specialty care (rheumatology or orthopedic
